Literature DB >> 11081587

Centrosome hyperamplification in head and neck squamous cell carcinoma: a potential phenotypic marker of tumor aggressiveness.

L M Gustafson1, L L Gleich, K Fukasawa, J Chadwell, M A Miller, P J Stambrook, J L Gluckman.   

Abstract

OBJECTIVES/HYPOTHESIS: There is currently no single histological or genotypic marker that reliably predicts the biological behavior of head and neck squamous cell carcinoma (HNSCC). While multiple genetic mutations have been investigated, no single genotypic alteration has consistently correlated with tumor aggressiveness. Phenotypic markers may prove more predictive, because they can represent many different genetic alterations. We investigated the frequency of centrosome hyperamplification in HNSCC and examined its usefulness as a marker for tumor recurrence. STUDY
DESIGN: Analysis of archived paraffin blocks using immunohistochemistry.
METHODS: Eighteen patients who underwent resection of oral cavity squamous cell carcinoma were reviewed. Ten patients had cancers that recurred locally within 1 year of resection, and 8 patients were tumor free at 5 years. The amount of centrosome hyperamplification in the cancer specimens and all surgical margins was graded as follows: 0, none; 1+, rare hyperamplification; 2+, greater than 10% of cells per high-powered field; and 3 +, greater than 20% of cells per high-powered field.
RESULTS: Centrosome hyperamplification was found in 17 of 18 tumors (94%). Grade 2+ or 3+ hyperamplification was found more in cancers that recurred (9 of 10) than in those that did not (3 of 8) and was more prevalent in the histologically normal margins of patients with recurrence (8 of 10) than in those without recurrent cancer (3 of 8).
CONCLUSIONS: Our results demonstrate the extremely frequent occurrence of centrosome hyperamplification in HNSCC. Centrosome hyperamplification is a phenotypic marker for HNSCC and can reflect multiple genotypic changes. Its presence in histologically normal margins suggests that it may be useful for analysis of primary tumors and tumor margins.

Entities:  

Mesh:

Year:  2000        PMID: 11081587     DOI: 10.1097/00005537-200011000-00004

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  12 in total

Review 1.  How to be good at being bad: centrosome amplification and mitotic propensity drive intratumoral heterogeneity.

Authors:  Padmashree C G Rida; Guilherme Cantuaria; Michelle D Reid; Omer Kucuk; Ritu Aneja
Journal:  Cancer Metastasis Rev       Date:  2015-12       Impact factor: 9.264

2.  Clinical implication of centrosome amplification in plasma cell neoplasm.

Authors:  Wee J Chng; Greg J Ahmann; Kim Henderson; Rafael Santana-Davila; Philip R Greipp; Morie A Gertz; Martha Q Lacy; Angela Dispenzieri; Shaji Kumar; S Vincent Rajkumar; John A Lust; Robert A Kyle; Steven R Zeldenrust; Suzanne R Hayman; Rafael Fonseca
Journal:  Blood       Date:  2005-12-22       Impact factor: 22.113

3.  Results of buccal micronucleus cytome assay in pesticide-exposed and non-exposed group.

Authors:  Hayal Cobanoglu; Munevver Coskun; Mahmut Coskun; Akin Çayir
Journal:  Environ Sci Pollut Res Int       Date:  2019-05-11       Impact factor: 4.223

Review 4.  Updated overview of current biomarkers in head and neck carcinoma.

Authors:  Kiran Dahiya; Rakesh Dhankhar
Journal:  World J Methodol       Date:  2016-03-26

Review 5.  Centrosome amplification and the origin of chromosomal instability in breast cancer.

Authors:  Jeffrey L Salisbury; Antonino B D'Assoro; Wilma L Lingle
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-07       Impact factor: 2.673

Review 6.  Centrosomes and myeloma; aneuploidy and proliferation.

Authors:  Wee J Chng; Rafael Fonseca
Journal:  Environ Mol Mutagen       Date:  2009-10       Impact factor: 3.216

Review 7.  A clinical overview of centrosome amplification in human cancers.

Authors:  Jason Yongsheng Chan
Journal:  Int J Biol Sci       Date:  2011-10-16       Impact factor: 6.580

8.  Mitosis phase enrichment with identification of mitotic centromere-associated kinesin as a therapeutic target in castration-resistant prostate cancer.

Authors:  Kanishka Sircar; Heng Huang; Limei Hu; Yuexin Liu; Jasreman Dhillon; David Cogdell; Armen Aprikian; Eleni Efstathiou; Nora Navone; Patricia Troncoso; Wei Zhang
Journal:  PLoS One       Date:  2012-02-17       Impact factor: 3.240

9.  Rampant centrosome amplification underlies more aggressive disease course of triple negative breast cancers.

Authors:  Vaishali Pannu; Karuna Mittal; Guilherme Cantuaria; Michelle D Reid; Xiaoxian Li; Shashikiran Donthamsetty; Michelle McBride; Sergey Klimov; Remus Osan; Meenakshi V Gupta; Padmashree C G Rida; Ritu Aneja
Journal:  Oncotarget       Date:  2015-04-30

Review 10.  Centrosome amplification: a quantifiable cancer cell trait with prognostic value in solid malignancies.

Authors:  Karuna Mittal; Jaspreet Kaur; Meghan Jaczko; Guanhao Wei; Michael S Toss; Emad A Rakha; Emiel Adrianus Maria Janssen; Håvard Søiland; Omer Kucuk; Michelle Dian Reid; Meenakshi V Gupta; Ritu Aneja
Journal:  Cancer Metastasis Rev       Date:  2020-10-26       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.